anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Rencofilstat
Trial phase: Phase 2
SMILES: [H][C@]1([C@H](O)[C@H](C)CCCCCCNC(C)=O)C(=O)N[C@@H](CC)C(=O)N(C)[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 15
Group description: CRV431, softgel capsule, 75mg, QD, 28 days, fasted conditions

CRV431 75mg: 1 x 75mg softgel capsule
Eligibility criteria:
Key Inclusion Criteria:

Male or female between 18 and 75 years of age (inclusive).
Capable of giving written informed consent and able to effectively communicate with the investigator and study personnel.
Presumed F2/F3 NASH to include: AST >20 IU/L, Pro-C3 >15.5 ng/mL, enhanced liver fibrosis (ELF) score >9.8, and FibroScan >8.5 kPa values.

Key Exclusion Criteria:

Pregnant or breastfeeding or planning to become pregnant during the study period.
Known allergy to CRV431, cyclosporine, or any of their inactive ingredients.
Positive test for hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (HCVAb) or human immunodeficiency virus antibodies (HIVAb).
Well documented causes of chronic liver disease according to standard diagnostic procedures to include any history or presence of decompensated cirrhosis.
Subjects with a platelet count <150,000/mL.
Subjects with hemoglobin A1c(HbA1c) >9.5%.
Weight loss of more than 5% within 3 months prior to randomization.
Subjects with a blood pressure to include a systolic pressure >150 or a diastolic pressure >90.
At Screening, an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 mL (calculated by the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] method) and/or a Kidney Disease Improving Global Outcomes (KDIGO) category of >G2.
Subjects with a history of organ transplantation. Corneal transplantation will be allowed.
Intervention: Rencofilstat
Trial phase: Phase 2
SMILES: [H][C@]1([C@H](O)[C@H](C)CCCCCCNC(C)=O)C(=O)N[C@@H](CC)C(=O)N(C)[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 17
Group description: CRV431, softgel capsule, 225mg, QD, 28 days, fasted conditions

CRV431 225mg: 3 x 75mg softgel capsule
Eligibility criteria:
Key Inclusion Criteria:

Male or female between 18 and 75 years of age (inclusive).
Capable of giving written informed consent and able to effectively communicate with the investigator and study personnel.
Presumed F2/F3 NASH to include: AST >20 IU/L, Pro-C3 >15.5 ng/mL, enhanced liver fibrosis (ELF) score >9.8, and FibroScan >8.5 kPa values.

Key Exclusion Criteria:

Pregnant or breastfeeding or planning to become pregnant during the study period.
Known allergy to CRV431, cyclosporine, or any of their inactive ingredients.
Positive test for hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (HCVAb) or human immunodeficiency virus antibodies (HIVAb).
Well documented causes of chronic liver disease according to standard diagnostic procedures to include any history or presence of decompensated cirrhosis.
Subjects with a platelet count <150,000/mL.
Subjects with hemoglobin A1c(HbA1c) >9.5%.
Weight loss of more than 5% within 3 months prior to randomization.
Subjects with a blood pressure to include a systolic pressure >150 or a diastolic pressure >90.
At Screening, an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 mL (calculated by the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] method) and/or a Kidney Disease Improving Global Outcomes (KDIGO) category of >G2.
Subjects with a history of organ transplantation. Corneal transplantation will be allowed.
Intervention: Roxadustat
Trial phase: Phase 3
ATC code: B03XA05
SMILES: Cc1nc(C(=O)NCC(=O)O)c(O)c2ccc(Oc3ccccc3)cc12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 283
Group description: Participants received roxadustat as an oral tablet, TIW for up to a maximum of 24 weeks. If a participant required roxadustat <60 mg/week to maintain Hb levels, the dose frequency was reduced in a stepwise manner, for example, to BIW, and then QW. For participants converted from an ESA, the initial roxadustat dose was based on the average prescribed ESA dose in the last 4 weeks (for epoetin alfa and darbepoetin alfa) or 8 weeks (for Mircera®). For participants with <6 weeks of prior ESA use, the initial roxadustat dose was based on a 2-tiered, weight-based dosing scheme. Dose adjustment evaluations were made every 4 weeks and doses were titrated based on Hb level and rate of Hb change. The prescribed dose did not exceed the maximum allowable dose of 3.0 mg/kg/dose or 400 mg per dose, whichever was lower.
Eligibility criteria:
Key Inclusion Criteria:

Receiving chronic dialysis for end stage renal disease (ESRD)
Vascular access must be a functioning native arteriovenous fistula or graft with adequate flow in the opinion of the investigator, or permanent tunnelled catheter
Screening Hb criteria: Participants converting from an ESA: between 9.0 to 12.0 grams (g)/deciliter (dL); Participants initiating anemia treatment: < 10.0 g/dL
Ferritin ≥ 50 nanograms (ng)/mililiter (mL), Transferrin saturation (TSAT) ≥ 10% at screening
Participant's alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are ≤ 3 x upper limit of normal (ULN), and total bilirubin (TBL) is ≤ 1.5 x ULN at screening and prior to initiating roxadustat treatment.
Body weight between 45.0 to 160.0 kg

Key Exclusion Criteria:

Red blood cell (RBC) transfusion within 4 weeks prior to enrollment
Known history of myelodysplastic syndrome or multiple myeloma
Known hereditary hematologic disease or other known causes for anemia other than chronic kidney disease (CKD)
Known chronic inflammatory disease that is determined by the investigator to be the primary cause of anemia
Active or chronic gastrointestinal bleeding
Treated with iron-chelating agents within 4 weeks prior to enrollment
History of New York Heart Association (NYHA) Class III or IV congestive heart failure
History of myocardial infarction, acute coronary syndrome, stroke, seizure, or a thrombotic/thromboembolic event (excluding vascular dialysis access stenosis/thrombosis) within 12 weeks prior to enrollment
Uncontrolled hypertension, in the opinion of the Investigator
Participant has a diagnosis or suspicion (for example, complex kidney cyst of Bosniak Category II or higher) of renal cell carcinoma (Principal Investigator's discretion)
History of malignancy, except for cancers determined to be cured or in remission for ≥ 2 years, curatively resected basal cell or squamous cell skin cancers, cervical cancer in situ, or resected colonic polyps
Intervention: Simethicone
Trial phase: Phase 2
SMILES: CO[Si](C)(C)O[Si](C)(C)C.O=[Si]=O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 87
Group description: Treatment with simethicone (Espumisan®, 100 mg/ml, Berlin-Chemie / Menarini Polska Sp z o.o., Warsaw, Poland) for four weeks. Simethicone was administered 3-6 times per day with each treatment comprising 6 drops of the 100 mg/ml emulsion.

Simethicone Solution: Oral daily treatment for four weeks
Eligibility criteria:
Inclusion Criteria:

diagnosed for infantile colic according to Wessel's criteria

Exclusion Criteria:

previous treatment with probiotic or synbiotic
previous treatment with antibiotics
Intervention: Ubrogepant
Trial phase: Phase 3
ATC code: N02CD04
SMILES: C[C@@H]1[C@H](c2ccccc2)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 456
Group description: Ubrogepant 100mg: For each qualifying prodrome event, 2 compressed tablets containing 50 mg of ubrogepant will be taken orally when the participant is confident that a headache will follow within 1-6 hours
Eligibility criteria:
Inclusion Criteria:

At least a 1-year history of migraine with or without aura consistent with a diagnosis according to the ICHD-3 (International Classification of Headache Disorders 3rd edition)
Migraine onset before age 50 years
By history, the participant's migraines typically last between 4 and 72 hours if untreated or treated unsuccessfully and migraine episodes are separated by at least 48 hours of headache pain freedom
History of 2 to 8 migraine attacks per month with moderate to severe headache in each of the 3 months prior to the Screening Visit

Exclusion Criteria:

Difficulty distinguishing migraine headache from tension-type or other headaches
Participants who overuse medication for migraine defined as use of opioids or barbiturates > 2 days/month, triptans or ergots ≥ 10 days/month, or simple analgesics (eg, aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen) ≥ 15 days/month in the 3 months prior to Visit 1 per investigator's judgment
Has a history of migraine aura with diplopia or impairment of level of consciousness, hemiplegic migraine, or retinal migraine as defined by ICHD-3
A current diagnosis of chronic migraine as defined by ICHD-3 or a history of 15 or more headache days per month on average in the 6 months prior to Visit 1 in the investigator's judgment. A headache day is defined as a day in which there was any occurrence of a headache of a minimum duration of 2 hours or a headache of any duration for which acute medication was taken
Has a current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy as defined by ICHD-3
Required hospital treatment of a migraine attack 3 or more times in the 6 months prior to Visit 1
History of malignancy in the 5 years prior to Visit 1, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer
History of any prior gastrointestinal conditions (eg, diarrhea syndromes, inflammatory bowel disease) that, per investigator judgment, may affect the absorption or metabolism of the study intervention; participants with prior gastric bariatric interventions (eg, Lap Band) which have been reversed are not excluded
Intervention: Cyclosporine
Trial phase: Phase 2
ATC code: L04AD01 | S01XA18
SMILES: CC=CCC(C)C(O)C1C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 30
Group description: Participants received Neoral 2.5mg/kg PO BID, based on the renal transplant dose for 7 days.

Neoral is an oral formulation of cyclosporine.
Eligibility criteria:
Inclusion Criteria:

3.1.1 Laboratory-confirmed SARS-CoV-2 infection within the past 10 days.

3.1.2 Patients admitted to non-ICU hospital floors or in an emergency department awaiting admission to a non-ICU hospital bed.

3.1.3 WHO COVID Scale Score 4 (Oxygen by mask or nasal prongs or WHO COVID Scale Score 5 (non-invasive ventilation or high-flow oxygen).

3.1.4 Age 18 to 90 years old.

3.1.5 ECOG (Eastern Cooperative Oncology Group) performance status ≤2 (see Appendix A).

3.1.6 Patients receiving or who have received standard of care therapy for COVID-19 can be included. This includes Remdesivir, Dexamethasone (or other steroids), and convalescent plasma.

3.1.7 Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

3.2.1 Allergy and/or hypersensitivity to CSA.

3.2.2 GFR<30 mL/min.

3.2.3 ALT (Alanine transaminase) or AST (Aspartate transaminase) >3X upper limits of normal.

3.2.4 Resistant hypertension (BP>140/90 mm Hg despite adherence to maximal doses of three antihypertensive agents).

3.2.5 Active bacterial or mycobacterial infection.

3.2.6 Pregnant and/or nursing patients. 3.2.7 Participation in a COVID-19 therapeutic drug trial.

3.2.8 Patients who have received or who are receiving anti-viral medications including hydroxychloroquine will not be excluded.

3.2.9 Patients with psychiatric illness/social situations that would limit compliance with study requirements.

3.2.10 Total cholesterol is < 100 (increased risk of seizure)

3.2.11 Concomitant dosing with Tacrolimus is a relative contraindication (increases overall immunosuppression and decrease seizure threshold

3.2.12 Concomitant malignancy is a relative contraindication (Neoral can increase susceptibility to development of neoplasia)

3.2.13 Inability to swallow oral medication

3.2.14 Treatment with immunomodulators or immunosuppressant drugs, including but not limited to IL-6 inhibitors, TNF inhibitors, anti-IL-1 agents, and JAK inhibitors.

3.2.15 Investigational Antiviral agents
Intervention: Bardoxolone methyl
Trial phase: Phase 2
SMILES: COC(=O)C12CCC(C)(C)CC1C1C(=O)C=C3C4(C)C=C(C#N)C(=O)C(C)(C)C4CCC3(C)C1(C)CC2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: Patients will be randomized using permuted block randomization in a 1:1 fashion to either once-daily administration of bardoxolone methyl (20 mg) or matching placebo

Bardoxolone Methyl: Once-daily administration of bardoxolone methyl (20mg)
Eligibility criteria:
Inclusion Criteria:

Laboratory-confirmed COVID-19 infection as determined by polymerase chain reaction (PCR)

Hospitalized patients that meets one of the following conditions:

Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.); OR
At rest, blood oxygen saturation ≤ 94%; OR
Require supplemental oxygen; OR
Requiring non-invasive ventilation; OR
Requiring invasive mechanical ventilation for up to 2 days.
Age ≥ 18 years. Enrollment of patients ≥70 years of age may be limited (e.g., comprise no more than 10% of all randomized patients), pending safety review by the DSMB and executive committee
Participant or legally authorized representative is willing to give informed consent

Exclusion Criteria:

Intubated and on invasive mechanical ventilation for three or more days at the time of randomization
Known left ventricular ejection fraction (LVEF) <40% or prior hospitalization for heart failure
Cardiac arrest
Shock
Known uncontrolled bacterial, fungal, or non-COVID viral infection
eGFR <30 ml/min/1.73 m² or requiring dialysis
ALT or AST > 5X ULN
History of cirrhosis, chronic active hepatitis or severe hepatic disease
Pregnant or lactating women
Enrolled in other trial of unapproved therapies, unless approved by trial Principal Investigator. In general, co-enrollment will be permitted unless there are safety concerns, mechanistic incompatibility or inability to adjudicate serious adverse events and will be decided on a case by case basis.
If in the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments
Intervention: Pregabalin
Trial phase: Phase 4
ATC code: N02BF02 | N03AX16
SMILES: CC(C)C[C@H](CN)CC(=O)O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 27
Group description: Patients were randomly allocated to Group P(1) - Pregabalin 300mg by a double blind randomized study. Group P(1) received two tablets of pregabalin 150mg, 02h before the start of the anesthesic-surgical procedure in identical sealed envelops, only identified as medication A or B

Pregabalin 300mg: Group P1 will receive a 300 mg tablet of pregabalin, 02h before the surgical procedure
Eligibility criteria:
Inclusion Criteria:

Patients who will undergo elective abdominal hysterectomy surgery due to benign pathologies;
Be classified as physical status by the Society of Anesthesiologists (ASA) as ASA I (healthy individual) or ASA II (patient with mild and controlled systemic disease);

Exclusion Criteria:

Allergy or intolerance previously known to pregabalin or opioids;
Patients with chronic pain or fibromyalgia;
Patients on chronic opioid use;
Carriers of malignant neoplasms;
Pregnant women;
People with active uncontrolled cardiovascular disease;
Patients with kidney and / or liver disease;
Patients who have spinal deformities that make spinal anesthesia impossible;
Presence of coagulation disorders or anticoagulant therapy that cannot be suspended for surgery;
Presence of active sepsis.
Intervention: Acalabrutinib
Trial phase: Phase 1
ATC code: L01EL02
SMILES: CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 9
Group description: Acalabrutinib with Best Supportive Care also with the Proton-Pump Inhibitor(PPI) treatment.
Eligibility criteria:
Inclusion Criteria:

Participant or legally authorized representative must be able to understand the purpose and risks of the study and provide written informed consent and authorization to use protected health information (in accordance with national and local patient privacy regulations).

Participants who are hospitalized with coronavirus (SARS-CoV-2) infection, confirmed by PCR test or other commercial or public health assay in any specimen, as documented by either of the following:

PCR positive in sample collected < 72 hours prior to first dose, OR

PCR positive in sample collected ≥ 72 hours prior to first dose (but no more than 14 days prior to first dose), documented inability to obtain a repeat sample (eg, due to lack of testing supplies, limited testing capacity, results taking > 24 hours, etc), AND progressive disease suggestive of ongoing SARS-CoV-2 infection 3 Evidence of respiratory failure attributable to COVID-19 pneumonia (documented radiographically) before enrollment 4 Nasogastric tube or other types of oral or percutaneous gastric feeding tube; placement must be radiographically confirmed and expected to remain in place, as judged by the investigator, for a minimum of 3 days after study enrolment.

5 Has received treatment with PPIs (eg, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole) for a minimum of 24 hours immediately prior to enrollment; any PPI will be permitted, provided it meets the minimum equivalent daily dose of 20 mg rabeprazole.

Exclusion Criteria:

Any serious and uncorrectable medical condition or abnormality of clinical laboratory tests that, in the Investigator's judgment, precludes the participant's safe participation in and completion of the study.
In the opinion of the Investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments.
Current refractory nausea and vomiting, malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
Received BTK inhibitor within 7 days before enrollment.
Requires or is receiving anticoagulation with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon) within 7 days prior to enrollment. Other anticoagulants are permitted.
Participants on dual antiplatelet and therapeutic anticoagulant therapy (eg, aspirin and therapeutic doses of low molecular weight heparin are not allowed; however, aspirin and prophylactic/ low doses of low-molecular-weight heprin are allowed).
Intervention: Netarsudil
Trial phase: Phase 2
ATC code: S01EE51 | S01EX05
SMILES: Cc1ccc(C(=O)OCc2ccc([C@@H](CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: One drop of study artificial tear in the study eye in the morning, and one drop of Netarsudil 0.02% ophthalmic solution in the study eye in the evening for an 8 week period in up to 20 subjects.

Netarsudil Ophthalmic: Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution
Eligibility criteria:
Inclusion Criteria:

Adults aged 18 years or older
Documented diagnosis of FCD
Evidence of central corneal edema, in at least one eye, at the Screening and Baseline Visit, in the eligible eye(s)
Reduced BCVA secondary to central corneal edema, at Screening and Baseline, in the eligible eye(s)

Exclusion Criteria:

FCD so advanced that, in the opinion of the Investigator, surgery would likely be required in the study eligible eye(s) within the study period
Clinically significant ocular disease (other than FCD) or trauma in the eligible eye(s) which could interfere with study interpretation
History of ocular surgery within 6 months of the Screening Visit, or any prior corneal refractive surgery in the eligible eye(s)
Intervention: Netarsudil
Trial phase: Phase 2
ATC code: S01EE51 | S01EX05
SMILES: Cc1ccc(C(=O)OCc2ccc([C@@H](CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: One drop of Netarsudil 0.02% ophthalmic solution in the study eye in the morning and in the evening for an 8 week period in up to 20 subjects.

Netarsudil Ophthalmic: Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution
Eligibility criteria:
Inclusion Criteria:

Adults aged 18 years or older
Documented diagnosis of FCD
Evidence of central corneal edema, in at least one eye, at the Screening and Baseline Visit, in the eligible eye(s)
Reduced BCVA secondary to central corneal edema, at Screening and Baseline, in the eligible eye(s)

Exclusion Criteria:

FCD so advanced that, in the opinion of the Investigator, surgery would likely be required in the study eligible eye(s) within the study period
Clinically significant ocular disease (other than FCD) or trauma in the eligible eye(s) which could interfere with study interpretation
History of ocular surgery within 6 months of the Screening Visit, or any prior corneal refractive surgery in the eligible eye(s)
Intervention: Apixaban
Trial phase: Phase 3
ATC code: B01AF02
SMILES: COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 165
Group description: Anticoagulation: prophylactic dose Apixaban 2.5mg po bid
Eligibility criteria:
Inclusion:

COVID-19+ in past 14 days
Platelets > 100,000
eGFR > 30ml/min

Exclusion:

Hospitalized
Contradiction/ other indication for anti-coagulation
Pregnancy
Active cancer
Intervention: Apixaban
Trial phase: Phase 3
ATC code: B01AF02
SMILES: COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 164
Group description: Anticoagulation: therapeutic dose Apixaban 5.0mg po bid
Eligibility criteria:
Inclusion:

COVID-19+ in past 14 days
Platelets > 100,000
eGFR > 30ml/min

Exclusion:

Hospitalized
Contradiction/ other indication for anti-coagulation
Pregnancy
Active cancer
Intervention: ASPIRIN
Trial phase: Phase 3
ATC code: A01AD05 | B01AC06 | B01AC56 | C07FX02 | C07FX03 | C07FX04 | C10BX01 | C10BX02 | C10BX04 | C10BX05 | C10BX06 | C10BX08 | C10BX12 | M01BA03 | N02AJ02 | N02AJ07 | N02AJ18 | N02BA01 | N02BA51 | N02BA71
SMILES: CC(=O)Oc1ccccc1C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 164
Group description: Antiplatelet agent: low dose aspirin 81mg po qd
Eligibility criteria:
Inclusion:

COVID-19+ in past 14 days
Platelets > 100,000
eGFR > 30ml/min

Exclusion:

Hospitalized
Contradiction/ other indication for anti-coagulation
Pregnancy
Active cancer